Eribulin - CAS 253128-41-5
Catalog number: B0084-305436
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C40H59NO11
Molecular Weight:
729.9
COA:
Inquire
Targets:
Microtubule/Tubulin
Description:
Eribulin suppressed centromere dynamics at concentrations that arrest mitosis. At 60 nmol/L eribulin (2 x mitotic IC(50)), the relaxation rate was suppressed 21%, the time spent paused increased 67%, and dynamicity decreased 35% (but without reduction in mean centromere separation), indicating that eribulin decreased normal microtubule-dependent spindle tension at the kinetochores, preventing the signal for mitotic checkpoint passage. [(3)H]eribulin binds soluble tubulin at a single site; however, this binding is complex with an overall K(d) of 46 microM, but also showing a real or apparent very high affinity (K(d) = 0.4 microM) for a subset of 25% of the tubulin. Eribulin also binds microtubules with a maximum stoichiometry of 14.7 +/- 1.3 molecules per microtubule (K(d) = 3.5 microM), strongly suggesting the presence of a relatively high-affinity binding site at microtubule ends. At 100 nM, the concentration that inhibits microtubule plus end growth by 50%, we found that one molecule of eribulin is bound per two microtubules, indicating that the binding of a single eribulin molecule at a microtubule end can potently inhibit its growth. Eribulin does not suppress dynamic instability at microtubule minus ends. Eribulin's in vivo superiority derives from its ability to induce irreversible mitotic blockade, which appears related to persistent drug retention and sustained Bcl-2 phosphorylation.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-305436 1 mg $998 In stock
Bulk Inquiry
Purity:
>98%
Synonyms:
Halaven; B1939; E7389; ER-086526
MSDS:
Inquire
InChIKey:
UFNVPOGXISZXJD-JBQZKEIOSA-N
InChI:
InChI=1S/C40H59NO11/c1-19-11-24-5-7-28-20(2)12-26(45-28)9-10-40-17-33-36(51-40)37-38(50-33)39(52-40)35-29(49-37)8-6-25(47-35)13-22(42)14-27-31(16-30(46-24)21(19)3)48-32(34(27)44-4)15-23(43)18-41/h19,23-39,43H,2-3,5-18,41H2,1,4H3/t19-,23+,24+,25-,26+,27+,28+,29+,30-,31+,32-,33-,34-,35+,36+,37+,38-,39+,40+/m1/s1
Canonical SMILES:
CC1CC2CCC3C(=C)CC(O3)CCC45CC6C(O4)C7C(O6)C(O5)C8C(O7)CCC(O8)CC(=O)CC9C(CC(C1=C)O2)OC(C9OC)CC(CN)O
1.Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial.
Aftimos P1, Polastro L2, Ameye L3, Jungels C2, Vakili J2, Paesmans M3, van den Eerenbeemt J2, Buttice A2, Gombos A2, de Valeriola D2, Gil T2, Piccart-Gebhart M2, Awada A2. Eur J Cancer. 2016 Apr 20;60:117-124. doi: 10.1016/j.ejca.2016.03.010. [Epub ahead of print]
BACKGROUND: Eribulin is a non-taxane microtubule dynamics inhibitor that showed a survival benefit versus treatment of physician's choice in a phase III trial enrolling patients with metastatic breast cancer (MBC).
2.In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumab.
Ueda S1, Saeki T1, Takeuchi H1, Shigekawa T1, Yamane T2, Kuji I2, Osaki A1. Br J Cancer. 2016 May 3. doi: 10.1038/bjc.2016.122. [Epub ahead of print]
BACKGROUND: Eribulin mesylate (eribulin) is a first-in-class halichondrin B-based microtubule dynamics inhibitor. To compare the anti-angiogenic activity of eribulin to that of bevacizumab, we compared tumour vessel remodelling and reoxygenation between the two agents.
3.Patient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice Guide.
Ro J1, Cheng FT2, Sriuranpong V3, Villalon A4, Smruti BK5, Tsang J6, Yap YS7; Asian Working Group for Eribulin Clinical Guide. J Breast Cancer. 2016 Mar;19(1):8-17. doi: 10.4048/jbc.2016.19.1.8. Epub 2016 Mar 25.
Eribulin, an antimicrotubule chemotherapeutic agent, is approved for the treatment of pretreated metastatic breast cancer (mBC) based on the positive outcomes of phase II and phase III clinical trials, which enrolled mainly Western patients. Eribulin has recently been approved in an increasing number of Asian countries; however, there is limited clinical experience in using the drug in certain countries. Therefore, we established an Asian working group to provide practical guidance for eribulin use based on our clinical experience. This paper summarizes the key clinical trials, and the management recommendations for the reported adverse events (AEs) of eribulin in mBC treatment, with an emphasis on those that are relevant to Asian patients, followed by further elaboration of our eribulin clinical experience. It is anticipated that this clinical practice guide will improve the management of AEs resulting from eribulin treatment, which will ensure that patients receive the maximum treatment benefit.
4.Antimitotic and Non-mitotic Effects of Eribulin Mesilate in Soft Tissue Sarcoma.
Kawano S1, Asano M1, Adachi Y1, Matsui J2. Anticancer Res. 2016 Apr;36(4):1553-61.
BACKGROUND: Eribulin mesilate (eribulin), a first-in-class halichondrin B-based microtubule dynamics inhibitor, has been shown to promote vascular remodeling and reversal of epithelial-mesenchymal transition (EMT) apart from its antimitotic activity in breast cancer models.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Microtubule/Tubulin Products


CAS 148408-66-6 Docetaxel Trihydrate

Docetaxel Trihydrate
(CAS: 148408-66-6)

Docetaxel is a cytotoxic agent, which is related to its ability to promote the formation of microtubule bundles and induce sustained mitotic arrest, followed by...

Dolastatin 10 trifluoroacetate

Dolastatin 10 trifluoroacetate inhibits tubulin polymerization and induces tubulin aggregation in vitro.

CAS 117048-59-6 Combretastatin A4

Combretastatin A4
(CAS: 117048-59-6)

Combretastatin A4, under the IUPAC name 2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenol, inhibits tubulin polymerization (IC50= 2.2 μM). It has demons...

CAS 313367-92-9 UA 62784

UA 62784
(CAS: 313367-92-9)

UA 62784, under the IUPAC name 4-[5-(4-methoxyphenyl)-1,3-oxazol-2-yl]fluoren-9-one, a cytotoxic microtubule inhibitor in vitro, causes reversible cell cycle ar...

CAS 61-73-4 Methylene Blue

Methylene Blue
(CAS: 61-73-4)

Methylene Blue, whose brand name is Calbiochem, inhibits tau filament formation (IC50 = 1.9 μM) and soluble guanylyl cyclase.

PBOX-15
(CAS: 354759-10-7)

PBOX-15 is a novel microtubule inhibitor, which induces apoptosis, upregulates death receptors, and potentiates TRAIL-mediated apoptosis in multiple myeloma cel...

CAS 714272-27-2 Plinabulin

Plinabulin
(CAS: 714272-27-2)

Plinabulin is a vascular disrupting agent (VDA) against tubulin-depolymerizing with IC50 value of 9.8~18 nM in tumor cells under the development of Nereus Pharm...

CAS 33069-62-4 Paclitaxel

Paclitaxel
(CAS: 33069-62-4)

Paclitaxel, derived from the bark of the Pacific yew tree, has a broad antineoplastic spectrum used in cancer chemotherapy. It promotes and stabilizes tubulin p...

Chemical Structure

CAS 253128-41-5 Eribulin

Quick Inquiry

Verification code

Featured Items